Louisiana State Employees Retirement System Invests $1.06 Million in Hologic, Inc. (NASDAQ:HOLX)

Louisiana State Employees Retirement System bought a new position in Hologic, Inc. (NASDAQ:HOLX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 14,800 shares of the medical equipment provider’s stock, valued at approximately $1,057,000.

Several other hedge funds and other institutional investors have also modified their holdings of HOLX. Qube Research & Technologies Ltd boosted its position in shares of Hologic by 117.2% in the third quarter. Qube Research & Technologies Ltd now owns 1,378,258 shares of the medical equipment provider’s stock worth $95,651,000 after buying an additional 743,557 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Hologic by 90.4% during the third quarter. Assenagon Asset Management S.A. now owns 845,493 shares of the medical equipment provider’s stock worth $58,677,000 after acquiring an additional 401,486 shares in the last quarter. Victory Capital Management Inc. raised its holdings in shares of Hologic by 8.9% during the third quarter. Victory Capital Management Inc. now owns 4,838,090 shares of the medical equipment provider’s stock worth $335,763,000 after acquiring an additional 393,371 shares in the last quarter. Clearbridge Investments LLC purchased a new stake in shares of Hologic during the third quarter worth $25,398,000. Finally, American Century Companies Inc. raised its holdings in shares of Hologic by 35.5% during the third quarter. American Century Companies Inc. now owns 1,080,073 shares of the medical equipment provider’s stock worth $74,957,000 after acquiring an additional 283,241 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analysts Set New Price Targets

HOLX has been the topic of several recent research reports. Evercore ISI raised their target price on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and raised their target price for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. UBS Group raised their target price on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. William Blair restated an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Finally, StockNews.com lowered Hologic from a “buy” rating to a “hold” rating in a report on Friday, March 8th. Six investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Hologic presently has an average rating of “Hold” and a consensus price target of $87.00.

Insider Activity

In other news, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the sale, the director now directly owns 48,611 shares in the company, valued at approximately $3,670,130.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the sale, the director now owns 48,611 shares in the company, valued at $3,670,130.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,846 shares of company stock worth $2,473,443. Company insiders own 1.75% of the company’s stock.

Hologic Trading Up 1.3 %

HOLX stock opened at $77.19 on Wednesday. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $87.88. The firm has a market cap of $18.12 billion, a P/E ratio of 36.58, a P/E/G ratio of 2.55 and a beta of 1.00. The business’s 50 day moving average is $75.87 and its 200-day moving average is $72.69. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. During the same period in the prior year, the company posted $1.07 EPS. The company’s revenue was down 5.7% compared to the same quarter last year. Equities analysts anticipate that Hologic, Inc. will post 4.01 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.